生命科学资讯

Belite brings FDA filing into view with phase 3 Stargardt disease victory

GE HealthCare, Philips, Siemens spotlight AI-forward imaging at RSNA 2025

Researchers find chronic stress you can see using a CT scan

Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline

Comparative Study of Two Innovative Single-Cell RNA Platforms - Bioengineer.org

Rothschild & Co Redburn Adjusts Price Target on Agilent Technologies to $180 From $165, Maintains Buy Rating - MarketScreener

Med-tech gainers and losers for Nov. 24-26, 2025

Lilly slightly lowers self-pay prices for single-dose vials of Zepbound

Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight - WebWire

Thermo Fisher Scientific launches CorEvitas Clinical Registry for rare autoimmune disorder - scientistlive.com

Holiday notice

Biopharma Sentiment Index | Q4 2025

"Heavy AI" is taking over biopharma | Signal Pulse Report

Introducing Endpoints Signal — intelligence for fresh biopharma insights

Belite continues ascent as Stargardt drug hits mark in late-stage trial

Agilent Announces 21 Cfr Part 11 Compliance Software For Xcelligence RTCA eSight - TradingView

A drugmaker charts a path through pharma’s ethical minefields

YuviTal wins Roche-backed breast cancer innovation challenge - JNS.org

Mackenzie Financial Corp Cuts Position in Agilent Technologies, Inc. $A - MarketBeat

Protego plans pivotal trial for AL amyloidosis prospect with $130M series B